Metabolon and Muses Lab Partner to Advance Platform for Treatment of Early Alzheimer’s

Metabolon and Muses Lab Partner to Advance Platform for Treatment of Early Alzheimer’s
Muses Labs and Metabolon announced they have entered into a partnership to assess the application of metabolomics in people with early symptoms of cognitive decline and Alzheimer’s disease (AD). Metabolomics measures changes in levels of metabolites (small molecules) and maps them to specific biochemical pathways to give clinicians a better understanding of a person's overall health and the influence of on health of genes, microbiome, diet, lifestyle and drug treatments. As such, metabolomics (literally, the study of metabolites) is a phenotyping technolo
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *